Retargeting adenoviruses for therapeutic applications and vaccines
Abstract
Adenoviruses (Ads) are robust vectors for therapeutic applications and vaccines, but their use can be limited by differences in their in vitro and in vivo pharmacologies. This review emphasizes that there is not just one Ad, but a whole virome of diverse viruses that can be used as therapeutics. It discusses that true vector targeting involves not only retargeting viruses, but importantly also detargeting the viruses from off‐target cells.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 03, 2020
- Source ID
- 10.1002/1873-3468.13731
Entities
People
- Jeffrey D. Rubin
- Michael A Barry
- Shao‐chia Lu
Organizations
- Congressionally Directed Medical Research Programs
- Mayo Clinic
- Mayo Clinic Graduate School of Biomedical Sciences